Company Nuo Therapeutics Inc OTC Bulletin Board
Equities
Biotechnology & Medical Research
End-of-day quote
Other stock markets
|
||
- USD | - |
|
20/05 | Nuo Therapeutics, Inc. announced that it has received $0.650875 million in funding | CI |
15/05 | Nuo Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024 | CI |
Business Summary
Sales per Business
USD in Million | 2022 | Weight | 2023 | Weight | Delta |
---|---|---|---|---|---|
Innovative Cell-based Technologies
100.0
%
| 0 | 100.0 % | 1 | 100.0 % | +442.12% |
Sales per region
USD in Million | 2022 | Weight | 2023 | Weight | Delta |
---|---|---|---|---|---|
United States
100.0
%
| 0 | 100.0 % | 1 | 100.0 % | +442.12% |
Managers
Managers | Title | Age | Since |
---|---|---|---|
David Jorden
CEO | Chief Executive Officer | 61 | 19/08/19 |
Peter Clausen
COO | Chief Operating Officer | 58 | 01/08/01 |
Members of the board
Members of the board | Title | Age | Since |
---|---|---|---|
C. Winzer
BRD | Director/Board Member | 67 | 30/09/30 |
David Jorden
CEO | Chief Executive Officer | 61 | 19/08/19 |
Paul Mintz
BRD | Director/Board Member | 75 | 07/17/07 |
Scott Pittman
BRD | Director/Board Member | 65 | 05/16/05 |
Share class
Vote | Quantity | Free-Float | Company-owned shares | Total Float | |
---|---|---|---|---|---|
Stock A | 1 | 45,466,238 | 18,981,995 ( 41.75 %) | 0 | 41.75 % |
Company contact information
![address Nuo Therapeutics Inc](https://cdn.zonebourse.com/static/address/18575656.png)
Sector
1st Jan change | Capi. | |
---|---|---|
+16.84% | 121B | |
+17.56% | 110B | |
+17.23% | 25.98B | |
-24.64% | 19.27B | |
-18.56% | 15.99B | |
-18.60% | 15.66B | |
-47.75% | 14.5B | |
+57.06% | 14.47B | |
+5.24% | 13.91B |
- Stock Market
- Equities
- AURX Stock
- Stock
- Company Nuo Therapeutics Inc